The table as follows displays the main adverse drug reactions in women treated with Elonva in clinical trials according to system organ class and frequency; common (≥ 1%, < 10%), uncommon (≥ 0.1%, < 1%). (See Table 6.)
Click on icon to see table/diagram/image
There have been post-marketing reports of hypersensitivity reactions, both local and generalized, including rash.
In addition, ectopic pregnancy and multiple gestations have been reported. These are considered to be related to ART or subsequent pregnancy.
View ADR Monitoring Form